NINLARO^® (ixazomib) capsules 4mg I 3mg I 2.3mg

This site is intended for US healthcare professionals only.

NINLARO^® (ixazomib) capsules 4mg I 3mg I 2.3mg

This site is intended for US healthcare professionals only.

WHEN NAVIGATING THE DIFFICULTIES OF MULTIPLE MYELOMA IN THE REAL WORLD, YOU NEED

DURABLE STRENGTH

THE NINLARO^® (ixazomib) REGIMEN* OFFERS EXTENDED EFFICACY AND MANAGEABLE TOLERABILITY FOR THE TYPES OF PATIENTS YOU SEE EVERY DAY^1-4

LEADING THE WAY TO
EXTENDED EFFICACY
SAFETY
INFORMATION

Indication: NINLARO is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Limitations of Use: NINLARO is not recommended for use in the maintenance setting or in newly diagnosed multiple myeloma in combination with lenalidomide and dexamethasone outside of controlled clinical trials.
^*The NINLARO regimen includes NINLARO+lenalidomide+dexamethasone.

Indication: NINLARO is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Limitations of Use: NINLARO is not recommended for use in the maintenance setting or in newly diagnosed multiple myeloma in combination with lenalidomide and dexamethasone outside of controlled clinical trials.
^*The NINLARO regimen includes NINLARO+lenalidomide+dexamethasone.

Takeda Oncology Patient Support Program

Your connection for coverage support, financial assistance, and educational resources.

Enrollment Form